It was first approved by the FDA for moderate‐severe asthma in 2003; subsequently, the approved indications have broadened and now include childhood asthma, chronic rhinosinusitis with nasal polyps, chronic urticaria and – since February 2024 – for IgE‐mediated food allergy in certain adults and children aged one year or older.9 This evidence concerns the gene IGHE and nasal cavity polyp.